Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

About this update from Verastem, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/ef2cc52ae8815dd77d0c1a3c8eff143e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bOdI2U9wfDoUTAgX2VooUg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ef2cc52ae8815dd77d0c1a3c8eff143e","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/DRn0zV0VY35EJDYUwC1QKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/ef2cc52ae8815dd77d0c1a3c8eff143e","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Based on preliminary, unaudited results, Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of approximately $17.5 million for the fourth quarter of 2025 and approximately $30.9 million for the full year 2025, following U.S. FDA approval in May 20251","length":264,"tagName":"p","attribs":{}},{"type":"text","content":"Company plans to continue rapidly advancing clinical development program for VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in several advanced KRAS G12D solid tumor indications","length":223,"tagName":"p","attribs":{}},{"type":"text","content":"Company sees preliminary unaudited cash, cash equivalents, and investments of $205 million as of December 31, 2025; pro-forma year-end cash, cash equivalents and investments of $234 million inclusive of net proceeds from exercise of expiring cash warrants; expected cash runway into first half of 2027","length":301,"tagName":"p","attribs":{}},{"type":"text","content":"Leadership to participate in a fireside chat at the Guggenheim Emerging Outlook Conference in New York City on February 11, 2026","length":128,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, February 04, 2026--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced preliminary, unaudited fourth quarter and full year 2025 net product revenues for AVMAPKI™ FAKZYNJA™ CO-PACK, business updates, and 2026 priorities.","length":358,"tagName":"p"},{"type":"text","content":""2025 was a tra...

More updates from Verastem, Inc.